TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27966269

Group type: COMPARATOR
Intervention: Blue-blocking intraocular lenses (IOL)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Neutral intraocular lenses (IOL)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Cataract surgery with blue-blocking IOLs
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Cataract surgery with neutral IOLs
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Cataract surgery
Number of subjects: 67
Study: 25740882

Group type: EXPERIMENTAL
Intervention: r‐FSH/r‐LH (Pergoveris(®)) 150/75 IU/day
Number of subjects: 240

Group type: COMPARATOR
Intervention: r‐FSH
Number of subjects: 240
Study: 23847256

Group type: EXPERIMENTAL
Intervention: AZD1480 (10-70 mg QD and 20-45 mg b.i.d.)
Number of subjects: 38
Study: 21030612

Group type: EXPERIMENTAL
Intervention: Monosodium glutamate (MSG) 2 g
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sodium chloride (NaCl)
Number of subjects: 13
Study: 19426177

Group type: EXPERIMENTAL
Intervention: Periodontal treatment before 21 weeks of gestation
Number of subjects: 812

Group type: COMPARATOR
Intervention: Periodontal treatment after delivery
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: Non-progressing group (no disease progression)
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: Progressing group (disease progression defined as >or=3 mm loss of clinical attachment)
Number of subjects: 812
Study: 16960174

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (5 mg/d as zinc sulfate)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 15248795

Group type: EXPERIMENTAL
Intervention: Experimental group received inservice training on facilitating peer interaction using verbal support strategies.
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group received training on adult‐child communication strategies.
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Experimental group (children) initiated interactions with peers more often and engaged in extended peer sequences more often than the control group (children).
Number of subjects: 17
Study: 11096377

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 2.5%
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 1%
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo, Hydrocortisone 1%, Hydrocortisone 2.5%
Number of subjects: 18
Study: 9075561

Group type: EXPERIMENTAL
Intervention: 100 mg rectally of diclofenac (n = 31)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (n = 31)
Number of subjects: 62
Study: 8471832

Group type: EXPERIMENTAL
Intervention: Pindolol 5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pindolol 10 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3816879

Group type: EXPERIMENTAL
Intervention: 300 mg intravenous infusion
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 300 mg oral solution
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 300 mg tablet administration
Number of subjects: 6
Study: 31931770

Group type: EXPERIMENTAL
Intervention: Self-regulated learning training
Number of subjects: 600

Group type: COMPARATOR
Intervention: Instructor-led training
Number of subjects: 600
Study: 29633099

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 63
Study: 28381155

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy intervention (9-month outpatient intervention)
Number of subjects: 751

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 751
Study: 26818900

Group type: COMPARATOR
Intervention: Traditional education
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Peer education (scenario 1)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Peer education (scenario 2)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Peer education (scenario 3)
Number of subjects: 199
Study: 23173717

Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT)
Number of subjects: 48
Study: 21927052

Group type: EXPERIMENTAL
Intervention: Epidural ketamine (30 mg, 3 mL) plus triamcinolone (80 mg, 2 mL) and bupivacaine (0.25%, 3 mL)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Epidural steroid injection (80 mg triamcinolone, 2 mL) and 0.25% bupivacaine (3 mL) plus saline (3 mL)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Epidural ketamine
Number of subjects: 200

Group type: COMPARATOR
Intervention: Epidural steroid injection with saline
Number of subjects: 200
Study: 18564342

Group type: EXPERIMENTAL
Intervention: Ezetimibe (EZE) 10 mg/day
Number of subjects: 1624

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1624
Study: 16612469

Group type: EXPERIMENTAL
Intervention: L-carnitine (CG)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo group (PG)
Number of subjects: 16
Study: 14564361

Group type: EXPERIMENTAL
Intervention: Raw maize hybrids
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Heat-treated maize hybrids
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Maize LTP
Number of subjects: 22
Study: 11018575

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 8898645

Group type: EXPERIMENTAL
Intervention: Ribavirin plus interferon alfa 2a (1200 mg oral ribavirin daily plus 3 million units of recombinant interferon alfa 2a thrice weekly for 24 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Interferon alfa 2a alone (3 million units thrice weekly for 24 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 60
Study: 1797521

Group type: EXPERIMENTAL
Intervention: Nicotine 0.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotine 1.0 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotine 2.0 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (0 mg)
Number of subjects: 0
Study: 6813902

Group type: EXPERIMENTAL
Intervention: Ad libitum smoking of a standard cigarette
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Smoking a standard cigarette with a prescribed puff pattern
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ad libitum smoking of their own cigarette
Number of subjects: 12
Study: 31987519

Group type: EXPERIMENTAL
Intervention: Back/front backpack design
Number of subjects: 12

Group type: COMPARATOR
Intervention: Back only backpack design
Number of subjects: 12
Study: 30747773

Group type: EXPERIMENTAL
Intervention: BMS-936559 (10-900 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: BMS-936559 (900 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: BMS-936559 (at two highest doses)
Number of subjects: 24
Study: 28160375

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 7913

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 7913
Study: 25500489

Group type: EXPERIMENTAL
Intervention: Marsh model
Number of subjects: 60

Group type: COMPARATOR
Intervention: Schnider model
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both models
Number of subjects: 60
Study: 23152491

Group type: EXPERIMENTAL
Intervention: Reduction in pulmonary capillary wedge pressure (PCWP)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Reduction in mean pulmonary artery pressure
Number of subjects: 233
Study: 21756381

Group type: EXPERIMENTAL
Intervention: Tadalafil rehabilitation (Group 2)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control without rehabilitation (Group 1)
Number of subjects: 65
Study: 19500154

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 1200 mg once-daily with digoxin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo with digoxin
Number of subjects: 12
Study: 16337719

Group type: EXPERIMENTAL
Intervention: MVA-BN (IMVAMUNE) vaccine, highest dose (10^8 TCID50)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: MVA-BN (IMVAMUNE) vaccine
Number of subjects: 86
Study: 15344392

Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg once a day
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg twice a day
Number of subjects: 57
Study: 10653828

Group type: EXPERIMENTAL
Intervention: Metoprolol CR
Number of subjects: 426
Study: 8369980

Group type: EXPERIMENTAL
Intervention: Oral cetirizine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inhaled cetirizine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3723261

Group type: EXPERIMENTAL
Intervention: 2:1 regimen (60 ml WHO‐ORS followed by 30 ml plain water)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Diluted WHO‐ORS (1.5 L water instead of 1 L)
Number of subjects: 50
Study: 31702432

Group type: EXPERIMENTAL
Intervention: Accelerated methotrexate, vinblastine, doxorubicin and cisplatin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Gemcitabine and carboplatin
Number of subjects: 30
Study: 30326762

Group type: EXPERIMENTAL
Intervention: Cognitive Task Analysis (CTA) tool
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard operative technique manual
Number of subjects: 22
Study: 27181606

Group type: EXPERIMENTAL
Intervention: Indacaterol (110 μg) plus Glycopyrronium (50 μg) once daily
Number of subjects: 3362

Group type: COMPARATOR
Intervention: Salmeterol (50 μg) plus Fluticasone (500 μg) twice daily
Number of subjects: 3362
Study: 24084500

Group type: COMPARATOR
Intervention: 0.5 mg intravitreal ranibizumab every 4 weeks (Rq4)
Number of subjects: 2457

Group type: EXPERIMENTAL
Intervention: 2 mg aflibercept every 4 weeks (2q4)
Number of subjects: 2457

Group type: EXPERIMENTAL
Intervention: 0.5 mg aflibercept every 4 weeks (0.5q4)
Number of subjects: 2457

Group type: EXPERIMENTAL
Intervention: 2 mg aflibercept every 8 weeks (2q8)
Number of subjects: 2457

Group type: EXPERIMENTAL
Intervention: All aflibercept and ranibizumab groups
Number of subjects: 2457

Group type: EXPERIMENTAL
Intervention: 2q8 aflibercept group
Number of subjects: 2457

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 2457
Study: 22112804

Group type: EXPERIMENTAL
Intervention: Vitamin D(3) (800 IU)
Number of subjects: 5292

Group type: EXPERIMENTAL
Intervention: Calcium (1000 mg)
Number of subjects: 5292
Study: 20738227

Group type: EXPERIMENTAL
Intervention: Dalcetrapib 900 mg with atorvastatin (concurrent dosing study)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Dalcetrapib 600 mg with atorvastatin (interval dosing study)
Number of subjects: 78
Study: 18219298

Group type: EXPERIMENTAL
Intervention: ECG strain and albuminuria present
Number of subjects: 7786

Group type: EXPERIMENTAL
Intervention: Only ECG strain present
Number of subjects: 7786

Group type: EXPERIMENTAL
Intervention: Only albuminuria present
Number of subjects: 7786

Group type: COMPARATOR
Intervention: Neither strain nor albuminuria present
Number of subjects: 7786

Group type: EXPERIMENTAL
Intervention: Both strain and albuminuria present
Number of subjects: 7786

Group type: EXPERIMENTAL
Intervention: Only strain present
Number of subjects: 7786
Study: 15689804

Group type: EXPERIMENTAL
Intervention: Oral steroids (for 1 week)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No oral steroids
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (after reoperation)
Number of subjects: 20
Study: 12908569

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 40
Study: 10588563

Group type: EXPERIMENTAL
Intervention: Continuous psoas compartment block (CPCB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional pain management with meperidine
Number of subjects: 40
Study: 8823700

Group type: EXPERIMENTAL
Intervention: Educational/cognitive intervention (ECO)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Educational discussion intervention (EDI)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Waiting list condition (WLC)
Number of subjects: 131
Study: 1395875

Group type: EXPERIMENTAL
Intervention: Surgery plus preoperative chemotherapy (5-FU 1g/m2/d x 5 and cisplatin 20 mg/m2/d x 5)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Surgery plus preoperative chemotherapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 46
Study: 3902911

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 29228369

Group type: EXPERIMENTAL
Intervention: Nicotine gum (4 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 10
Study: 28940820

Group type: EXPERIMENTAL
Intervention: ET with NIV
Number of subjects: 42

Group type: COMPARATOR
Intervention: ET alone
Number of subjects: 42
Study: 29653037

Group type: EXPERIMENTAL
Intervention: Manual Titration (MT) technique
Number of subjects: 90

Group type: COMPARATOR
Intervention: Target-Controlled Infusion (TCI)
Number of subjects: 90
Study: 23135529

Group type: EXPERIMENTAL
Intervention: Estrogen plus naltrexone (0.7 mg/kg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Estrogen alone
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo plus naltrexone (0.7 mg/kg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 42
Study: 22115988

Group type: EXPERIMENTAL
Intervention: Systematic ignoring with minimal check ('SI‐mc')
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Parental presence with minimal check ('PP‐mc')
Number of subjects: 16
Study: 20470677

Group type: EXPERIMENTAL
Intervention: FloSeal hemostatic matrix
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical clipping
Number of subjects: 0
Study: 18474932

Group type: EXPERIMENTAL
Intervention: Immediate-release methylphenidate (3 doses, twice daily for 2 weeks)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 16040376

Group type: EXPERIMENTAL
Intervention: Pergolide (0.05-0.2 mg per day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (one to four tablets per day)
Number of subjects: 42
Study: 12444336

Group type: EXPERIMENTAL
Intervention: Body-weight-independent (BWI) dosing of cyclosporine A (CsA) 100-300 mg for 12 weeks
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Body-weight-dependent (BWD) dosing of cyclosporine A (CsA) 1.25-5.0 mg/kg for 12 weeks
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Intermittent CsA treatment (after period I)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo treatment (after period I)
Number of subjects: 122
Study: 10606177

Group type: EXPERIMENTAL
Intervention: Brahma Rasayana (BR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated patients (control)
Number of subjects: 0
Study: 8602320

Group type: EXPERIMENTAL
Intervention: Physician-based intervention with self-help materials and goal-setting scripts
Number of subjects: 250

Group type: COMPARATOR
Intervention: Usual-care group (control)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Physician-based intervention
Number of subjects: 250
Study: 1294411

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 157

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 157
Study: 6207983

Group type: EXPERIMENTAL
Intervention: Propranolol (40-320 mg/day)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control group (no propranolol)
Number of subjects: 204
Study: 30710418

Group type: EXPERIMENTAL
Intervention: Regular professional brushing by a dental nurse every 2 weeks for 3 months (n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oral hygiene procedures performed/controlled by nursing home staff (n = 25)
Number of subjects: 50
Study: 28636435

Group type: EXPERIMENTAL
Intervention: Contrast training programme (isometric + plyometric), twice a week for 10 weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 58
Study: 27213949

Group type: EXPERIMENTAL
Intervention: Bupropion (300 mg/day) + Naltrexone (50 mg/day)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Bupropion (300 mg/day) + Placebo
Number of subjects: 121
Study: 24489770

Group type: EXPERIMENTAL
Intervention: Antibiotic combination therapy (amoxicillin, tetracycline, and metronidazole - ATM)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Antibiotic combination therapy (ATM)
Number of subjects: 20
Study: 22992449

Group type: EXPERIMENTAL
Intervention: Empowerment program (six-week intervention with four individual and two group counselling sessions)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Empowerment program (six-week intervention)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 48
Study: 21051252

Group type: EXPERIMENTAL
Intervention: Insulin infusion (1.6 mU/kg/h) for 4 hours before hemodialysis
Number of subjects: 5
Study: 17350775

Group type: EXPERIMENTAL
Intervention: Gaussian noise at levels from audible to inaudible (0.0 to -35.0 dB/Hz)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Uniform noise at levels from audible to inaudible (0.0 to -35.0 dB/Hz)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Very low noise levels (-30.0 to -35.0 dB/Hz)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quiet (no noise)
Number of subjects: 0
Study: 15563637

Group type: EXPERIMENTAL
Intervention: Arbitrary‐pressure CPAP based on body mass index before treatment polysomnography
Number of subjects: 91

Group type: COMPARATOR
Intervention: CPAP at settings determined by polysomnography
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Arbitrary‐pressure CPAP
Number of subjects: 91
Study: 12125474

Group type: EXPERIMENTAL
Intervention: Calcimax (200 mg per capsule, 2 capsules after light supper for 6 months)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 31
Study: 10427881

Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg i.m.
Number of subjects: 48

Group type: COMPARATOR
Intervention: Tramadol 1 mg/kg s.c.
Number of subjects: 48
Study: 7579506

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) 20 mg/day for 2 years
Number of subjects: 370

Group type: COMPARATOR
Intervention: No adjuvant hormone therapy
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM)
Number of subjects: 370
Study: 2223432

Group type: EXPERIMENTAL
Intervention: Nimodipine (calcium antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 7209768

Group type: COMPARATOR
Intervention: Ignore acid group - Proximal gastric vagotomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tailored group - Proximal gastric vagotomy if peak acid output < 40 mEq/hr; Vagotomy and antrectomy if peak acid output > 40 mEq/hr
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ignore acid group - Peak acid output > 40 mEq/hr
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ignore acid group - Peak acid output < 40 mEq/hr
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tailored group - Vagotomy plus antrectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tailored group - Proximal gastric vagotomy
Number of subjects: 0
Study: 30717365

Group type: EXPERIMENTAL
Intervention: Health-related information
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Information on bitterness-taste
Number of subjects: 205
Study: 28865313

Group type: EXPERIMENTAL
Intervention: Choice group (participants could choose the order of hands for trials)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (hand order determined by choice-group counterparts)
Number of subjects: 0
Study: 26923512

Group type: EXPERIMENTAL
Intervention: Fiber composite (FC) ingredient in a smoothie-type beverage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fiber composite (FC) ingredient in a cold-pressed snack bar
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maltodextrin (MD)
Number of subjects: 0
Study: 23800503

Group type: EXPERIMENTAL
Intervention: Aggressive blood pressure control
Number of subjects: 3020

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy
Number of subjects: 3020

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 3020
Study: 22228638

Group type: EXPERIMENTAL
Intervention: Sorafenib 200 mg twice daily plus temsirolimus 25 mg weekly (Arm A)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg every morning, 200 mg every night plus tipifarnib 100 mg twice daily (Arm B)
Number of subjects: 102
Study: 21187625

Group type: EXPERIMENTAL
Intervention: Allograft with Cyclosporine-A (CsA)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control site (Allograft alone)
Number of subjects: 15
Study: 17928091

Group type: EXPERIMENTAL
Intervention: Group A: rapid tapering and withdrawal 91 days after LT
Number of subjects: 39

Group type: COMPARATOR
Intervention: Group B: slow tapering and withdrawal 25 months after LT
Number of subjects: 39
Study: 16532676

Group type: EXPERIMENTAL
Intervention: Vitamin C status in asthmatic patients
Number of subjects: 100

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Duration of asthma
Number of subjects: 100
Study: 11823112

Group type: EXPERIMENTAL
Intervention: Levetiracetam 1000 mg/day
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Levetiracetam 2000 mg/day
Number of subjects: 324

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 324
Study: 9579769

Group type: EXPERIMENTAL
Intervention: Trandolapril (0.25 to 16 mg/day)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 322
Study: 7666079

Group type: EXPERIMENTAL
Intervention: Suramin and hydrocortisone (cohort A: loading dose followed by continuous infusion)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Suramin and hydrocortisone (cohort B: intermittent schedule)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Suramin and hydrocortisone (cohort C: empiric dosing regimen)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Suramin and hydrocortisone (all cohorts)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Suramin and hydrocortisone (sequential regimens)
Number of subjects: 56
Study: 2572047

Group type: EXPERIMENTAL
Intervention: Mesalazine treatment
Number of subjects: 8

Group type: COMPARATOR
Intervention: Salicylazosulfapyridine (SASP) treatment
Number of subjects: 8
Study: 598403

Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0